Literature DB >> 29660655

Urolithin A shows anti-atherosclerotic activity via activation of class B scavenger receptor and activation of Nef2 signaling pathway.

Guang-Hao Cui1, Wei-Qian Chen1, Zhen-Ya Shen2.   

Abstract

BACKGROUND: This study investigates the therapeutic potential of urothelin A in attenuating atherosclerotic lesion in wistar rat models and explore the role of Scavenger receptor-class B type I (SR-BI) and activation of Nrf-2 singling pathway.
METHODS: Wistar rats (n=48) were feed with high cholesterol diet supplemented with Vitamin D3 and subjected to balloon injury of the aorta. Three days prior to the aortal injury, rats (n=16) were administered urothelin A (3mg/kg/d; po). Positive control were rats receiving high cholesterol diet and balloon injury of the aorta (n=16). The sham group (n=16) consisted of rats fed on basal diet. After twelve weeks blood was collected from all animals for estimation of lipid and angiotensin II (Ang II) levels along, subsequently all animals were sacrificed and morphologic analysis of the aorta was performed. Expression of SR-BI and phosphorylated extracellular signal regulated kinase 1/2 (p-ERK1/2) protein were evaluated by Western blot.
RESULTS: After twelve weeks of treatment with urolithin A, there was a significant decrease in the plasma lipid and Ang II levels and improvement of aortic lesion compared with the sham group. There was an increased expression of SR-BI and inhibition of p-ERK1/2 (p<0.05). The expression of SR-BI was inversely correlated with levels of Ang II.
CONCLUSION: From the results it can be safely concluded that administration of urolithin A attenuates atherosclerosis via upregulation of SR-BI expression and inhibition of p-ERK1/2 levels.
Copyright © 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Cardiovascular disorders; Scavenger receptor class B; Urolithin

Mesh:

Substances:

Year:  2017        PMID: 29660655     DOI: 10.1016/j.pharep.2017.04.020

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  6 in total

1.  Human microbial metabolite mimicry as a strategy to expand the chemical space of potential drugs.

Authors:  Hao Li; Harmit S Ranhotra; Sridhar Mani; Zdeněk Dvořák; Harry Sokol; Rolf Müller
Journal:  Drug Discov Today       Date:  2020-06-17       Impact factor: 7.851

Review 2.  Gut Microbiota and Its Metabolites in Atherosclerosis Development.

Authors:  Magdalena D Pieczynska; Yang Yang; S Petrykowski; Olaf K Horbanczuk; Atanas G Atanasov; Jaroslaw O Horbanczuk
Journal:  Molecules       Date:  2020-01-29       Impact factor: 4.411

Review 3.  Effect of Gut Microbiota Biotransformation on Dietary Tannins and Human Health Implications.

Authors:  Ibrahim E Sallam; Amr Abdelwareth; Heba Attia; Ramy K Aziz; Masun Nabhan Homsi; Martin von Bergen; Mohamed A Farag
Journal:  Microorganisms       Date:  2021-04-29

4.  Urolithin and Reduced Urolithin Derivatives as Potent Inhibitors of Tyrosinase and Melanogenesis: Importance of the 4-Substituted Resorcinol Moiety.

Authors:  Sanggwon Lee; Heejeong Choi; Yujin Park; Hee Jin Jung; Sultan Ullah; Inkyu Choi; Dongwan Kang; Chaeun Park; Il Young Ryu; Yeongmu Jeong; YeJi Hwang; Sojeong Hong; Pusoon Chun; Hyung Ryong Moon
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

Review 5.  Coumarins as Modulators of the Keap1/Nrf2/ARE Signaling Pathway.

Authors:  Emad H M Hassanein; Ahmed M Sayed; Omnia E Hussein; Ayman M Mahmoud
Journal:  Oxid Med Cell Longev       Date:  2020-04-22       Impact factor: 6.543

Review 6.  Physiological and Immune Functions of Punicalagin.

Authors:  Eva Venusova; Adriana Kolesarova; Pavel Horky; Petr Slama
Journal:  Nutrients       Date:  2021-06-23       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.